Netupitant
【Chemical Name】Netupitant
【Original】Roche
【Time to market】2014.10.10
【Dosage and Usage】Capsules: 300 mg netupitant/0.5 mg palonosetron;
For Injection: 235 mg fosnetupitant/0.25 mg palonosetron as a lyophilized powder in single-dose vial for reconstitution
Injection: 235 mg fosnetupitant/0.25 mg palonosetron solution in single dose 20 mL vial
Used for the treatment of the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Netupitant
一、 Product Overview
Netupitant,developed by Roche for the treatment of the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.Its combination with palonosetron was approved by the US Food and Drug Administration (FDA) on Oct.10, 2014.
二、Main products
Description | Structural Formula | CAS No. | Category |
Netupitant |
| 290297-26-6 | API |
2-(3,5-bis(trifluoromethyl) phenyl)-2-methylpropanoic acid |
| 289686-70-0 | intermediates |
3-Pyridinecarboxamide, 4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- |
| 342417-01-0 | intermediates |
3-Pyridinamine,N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- |
| 290297-25-5 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.